DERL2

DERL2 (Derlin-2) is an ER transmembrane protein that functions as a core component of the ER-associated degradation (ERAD) dislocation machinery, linking misfolded substrate recognition to retrotranslocation and proteasomal disposal. It is transcriptionally induced by the IRE1 branch of the unfolded protein response and physically bridges EDEM (a misfolded glycoprotein receptor) and p97 (the cytosolic retrotranslocation ATPase), acting upstream of Derlin-1 in a Derlin-2→Derlin-1→Surf4→caveolin-1/p97 retrotranslocation cascade that handles substrates including misfolded glycoproteins, proinsulin, and COX-2 (PMID:16449189, PMID:37676109, PMID:26107514). Whole-body Derlin-2 knockout causes constitutive UPR activation, defective collagen secretion, and perinatal lethality in mice, while CNS-specific deletion impairs brain development by reducing SREBP-2-mediated cholesterol biosynthesis required for neurite outgrowth (PMID:21220515, PMID:34355142). Derlin-2 also facilitates ER-to-cytosol translocation of polyomavirus genomes and stabilizes the BAG6 co-chaperone through direct interaction (PMID:16912321, PMID:37815698).

1. 2006 High

   Identification of Derlin-2 as the missing physical link between the ER-luminal misfolded glycoprotein receptor EDEM and the cytosolic ATPase p97 established Derlin-2 as a central dislocation channel component in ERAD.

   Evidence Reciprocal co-immunoprecipitation of Derlin-2 with EDEM and p97; shRNA knockdown and overexpression with misfolded glycoprotein degradation assays; UPR induction showing IRE1-dependent upregulation

   PMID:16449189

   Open questions at the time

   • Whether Derlin-2 forms a true aqueous channel or merely organizes other pore components was not determined
   • The stoichiometry and topology of the Derlin-2 complex with EDEM and p97 remain unresolved
   • Relationship to the Derlin-1 paralog within the same pathway was not addressed
2. 2006 High

   Demonstrating that Derlin-2 is required for ER-to-cytosol translocation of polyomavirus DNA extended the retrotranslocation function beyond ERAD substrates to viral exploitation of the dislocation machinery.

   Evidence Dominant-negative Derlin-2 expression and shRNA knockdown blocking polyomavirus infection at the ER exit step; bypass by direct cytosolic DNA delivery

   PMID:16912321

   Open questions at the time

   • Whether Derlin-2 directly contacts the viral particle or acts indirectly through ERAD co-factors was not resolved
   • The specific viral substrate features recognized by Derlin-2 were not identified
3. 2011 High

   In vivo knockout established that Derlin-2 is essential for organismal viability and secretory function, with its loss triggering constitutive UPR activation and lethal skeletal dysplasia from defective collagen secretion.

   Evidence Whole-body conditional knockout mice; histological, molecular, and collagen secretion analysis in costal chondrocytes

   PMID:21220515

   Open questions at the time

   • Whether the perinatal lethality reflects failure to degrade specific ERAD substrates or a broader ER homeostasis collapse was not distinguished
   • Tissue-specific requirements beyond chondrocytes were not systematically examined
4. 2015 Medium

   Identifying proinsulin as a Derlin-2-dependent ERAD substrate broadened the known substrate repertoire to a hormone precursor relevant to diabetes pathophysiology.

   Evidence shRNA knockdown of Derlin-2, p97, and HRD1 with measurement of steady-state proinsulin levels

   PMID:26107514

   Open questions at the time

   • Direct physical interaction between Derlin-2 and proinsulin was not demonstrated
   • Whether misfolded or normal proinsulin is the ERAD target was not clarified
   • Single-lab finding without independent replication
5. 2017 Medium

   Showing that Derlin-2 deficiency in podocytes triggers caspase-12-dependent apoptosis under ER stress revealed that Derlin-2 is essential for adaptive ER stress management in terminally differentiated cells.

   Evidence Derlin-2 knockout and overexpression in podocytes with adriamycin injury; caspase-12 pathway analysis

   PMID:29167172

   Open questions at the time

   • The specific ERAD substrates accumulating in Derlin-2-deficient podocytes were not identified
   • Whether the caspase-12 activation is a direct or secondary consequence of ERAD failure was not distinguished
6. 2021 Medium

   CNS-specific Derlin-2 deletion revealed a non-canonical function: supporting SREBP-2-mediated cholesterol biosynthesis required for postnatal brain development and neurite outgrowth.

   Evidence CNS-conditional knockout mice; neurite outgrowth assays; SREBP-2 pathway rescue experiments

   PMID:34355142

   Open questions at the time

   • The mechanistic step at which Derlin-2 promotes SREBP-2 activation was not defined
   • Derlin-2-specific versus Derlin-1-specific contributions to cholesterol biosynthesis were not fully separated
7. 2023 High

   Epistasis mapping placed Derlin-2 upstream of Derlin-1 and Surf4 in a COX-2 retrotranslocation cascade and showed Derlin-2 interacts with COX-2 independently of N-glycosylation, resolving the order of dislocation steps and broadening substrate recognition beyond glycoprotein signals.

   Evidence CRISPR library screen; siRNA epistasis; co-IP of Derlin-2, Derlin-1, Surf4, caveolin-1, and p97 with COX-2; N-glycosylation mutant analysis; ubiquitylation assays

   PMID:37676109

   Open questions at the time

   • No structural data for the Derlin-2–Derlin-1–Surf4 complex
   • The signal on COX-2 recognized by Derlin-2 in the absence of N-glycosylation was not identified
8. 2023 Medium

   Discovery that Derlin-2 directly interacts with and stabilizes BAG6 co-chaperone revealed a protein quality control function extending beyond the classical ERAD dislocation channel, with relevance to cancer drug sensitivity.

   Evidence Co-immunoprecipitation of DERL2 with BAG6; cycloheximide chase showing extended BAG6 half-life; DERL2 knockout sensitizing cholangiocarcinoma cells to gemcitabine

   PMID:37815698

   Open questions at the time

   • Single-lab co-IP without reciprocal validation from an independent group
   • Whether BAG6 stabilization depends on Derlin-2's ERAD channel activity or a separate binding interface was not determined
   • In vivo relevance of the DERL2–BAG6 axis in tumor biology awaits confirmation in additional cancer models

• Key unresolved questions include the structural basis of the Derlin-2 dislocation channel, how Derlin-2 recognizes non-glycosylated substrates, and the mechanism by which Derlin-2 promotes SREBP-2 activation in the brain.
• No high-resolution structure of Derlin-2 or the Derlin-2-containing retrotranslocation complex exists
• The substrate recognition motif bound by Derlin-2 independently of N-glycosylation is unknown
• The mechanistic connection between Derlin-2 and SREBP-2 cleavage/activation has not been mapped